It’s not static, unilateral or absolutely foolproof. It’s a process worth embracing
As you might imagine, this is quite a time to be a scientist who does vaccine-related research. Usually, mentioning my chosen profession as an immunologist is the fastest way to get the crickets chirping at a cocktail party, but now I cannot get out of conversations with complete strangers in less than a half an hour if they find out what I do for a living.
I am actually grateful to have the chance to answer questions for people and gratified when it seems like the information I gave was useful or reassuring. Buried beneath the questions about how vaccines work, are they safe, will they change my genetic code, which ones have microchips in them, and will my cell phone reception be better after my first or second shot, I have noticed an undercurrent of unfamiliarity with science in general.
This year’s event is co-sponsored by CU Boulder and the CU Anschutz Medical Campus.
After being postponed in 2020 amid COVID-19, ScienceWriters2021 is on track for Oct. 8-11, 2021, at the University of Colorado Boulder and the University of Colorado Anschutz Medical Campus.
The annual conference is the nation’s premier science communications gathering and is organized by the Council for the Advancement of Science Writing (CASW) and the National Association of Science Writers (NASW) in coordination with a different research institution each year. This year, the event is co-sponsored by CU Boulder and the CU Anschutz Medical Campus.
The 2021 conference is expected to attract at least 300 in-person attendees and as many as 2,000 virtual attendees for several days of meetings, workshops, talks and tours.
Restoring blood component regeneration process could curb disease, lengthen people's healthspans Creating 200 billion-plus brand-new red blood cells a.
Study examines how N protein binds to viral RNA, manipulates host-cell machinery to enhance infection While the infamous SARS-CoV-2 spike protein grabs.
Clinical trial uses CAR-T cells made steps away at the Gates Biomanufacturing Facility
A new clinical trial at the University of Colorado Anschutz Medical Campus, using cells genetically engineered by medical faculty to fight stubborn cancers, is showing encouraging results.
Created at the Gates Biomanufacturing Facility a few steps from CU Anschutz, the chimeric antigen receptor T cells, or CAR-T cells, are being infused into patients with difficult to treat or frequently recurring cancers at UCHealth University of Colorado Hospital.
Heather Pidcoke was among
the locally produced
now has no cancer symptoms.
It’s the first cellular immunotherapy project where the developmental science, regulatory filing and approvals, manufacturing process and infusion of patients in clinical trials have all been done at CU Anschutz.